Accretion Pharmaceuticals Limited has scheduled a series of investor and analyst meetings in Mumbai on June 26, 2026. The management will participate in-person to discuss company performance and strategy, adhering to regulations that prohibit the disclosure of unpublished price sensitive information during these sessions.

The meetings were disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The schedule includes both one-on-one interactions and a group meeting, providing a platform for engagement with key market participants.

Discussions during these sessions will be based on generally available information. The company confirmed that the proceedings will comply with its Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information.

The schedule remains subject to change due to potential exigencies involving the company or the attending investors and analysts. Harshad Nanubhai Rathod, Director & CFO, signed the disclosure on behalf of accretion pharmaceuticals .

Promoters of accretion pharmaceuticals have confirmed that no shares were encumbered directly or indirectly during the financial year ended March 31, 2026. The declaration was submitted to the National Stock Exchange of India Limited on April 7, 2026, on behalf of all promoters and the promoter group, including persons acting in concert with them.

The disclosure was made in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, read with the SEBI (Substantial Acquisition of Shares and Takeovers) (Second Amendment) Regulations, 2019. This regulation requires promoters to annually disclose any encumbrance of shares held by them or the promoter group.

The declaration was signed by Harshad Nanubhai Rathod, Vivek Ashokkumar Patel, Hardik Mukundbhai Prajapati, and Mayur Popatlal Sojitra. Each promoter confirmed that they had not pledged or created any charge on their shareholdings during the specified period.

The letters were addressed to the Corporate Relations Department of the National Stock Exchange of India Limited. Copies of the disclosure were also marked to the Audit Committee of Accretion Pharmaceuticals Limited.

Key Disclosures